A study on fibromyalgia therapeutics has been conducted to understand the market landscape in 2022.

Kenneth Research
A study on fibromyalgia therapeutics has been conducted to understand the market landscape in 2022.

Survey period: October 22nd to October 29th, 2022
Researcher: RNPL Inc.
Survey Base: We surveyed 540 market players of all sizes.
Number of valid responses: 535
Survey method: field survey 265, internet survey 270
Survey Respondents: The survey was conducted among companies based on revenue. Survey results:
What are the symptoms associated with fibromyalgia?
Fibromyalgia is one of many chronic pain conditions characterized by widespread pain and tenderness that radiates throughout the body. It also causes symptoms such as fatigue, sleep, memory problems, depression, mood problems, pelvic pain, and digestive problems. Q: Which of the fibromyalgia medications is the most effective, according to research conducted? Fibromyalgia has no cure and is difficult to treat. However, it can be managed by treating symptoms with both pharmacological and non-pharmacological therapies. Drugs such as duloxetine (Cymbalta), milnacipran (Savella), and pregabalin (Lyrica) are specifically FDA-approved to treat fibromyalgia. Others include “off-label” (prescribed by doctors for observed benefits but not FDA-approved), pain relievers, antidepressants, anticonvulsants, and others. Also, natural therapies such as yoga/meditation, aerobic exercise, acupuncture, physical and cognitive-behavioral therapy (CBT), massage therapy, and Tai Chi have been shown to significantly improve symptoms. In most cases, the best results are achieved by using more than one type of treatment, or using them in combination with each other.
[Image 1d59861-3135-d6feafd25fe16f1abf22-0.png&s3=59861-3135-dd424d48c1dee3d8acc12e6fa960598f-565x360.png
Q: What are the latest breakthroughs in the treatment of fibromyalgia? According to the latest research, many of the symptoms of fibromyalgia syndrome (FMS) are triggered by antibodies that increase activity in pain-sensing nerves throughout the body. The findings conclude that fibromyalgia is a disease of the immune system and does not originate in the brain, as is currently understood.
A clinical study of the efficacy and safety of Ajovy (fremanezumab) in fibromyalgia patients has been successfully completed. It is a biological agent that comes as a liquid solution in prefilled syringes and autoinjection pens.
Considered a powerful pain reliever and hitherto avoided, opioids are effective in significantly improving fibromyalgia symptoms, according to new research. Many patients find relief with CBD-containing products.
Tonix Pharmaceuticals announces results of TNX-102 Phase 3 trial demonstrating efficacy in fibromyalgia.
Karabuk University, Turkey conducted a study on wet cupping therapy (WCT) for the treatment of fibromyalgia in collaboration with LEYMAN ESOY of Saglik Bilimuleri University.
Question: What are the factors driving the growth of the fibromyalgia drug market?
The main factors are:
Increased incidence of fibromyalgia
Fibromyalgia occurs in all populations worldwide and can affect all age groups. The prevalence of symptoms ranges from 2% to 4% in the general population. It is estimated that nearly 1 in 20 people may be affected by fibromyalgia. An estimated 4 million Americans (2% of the US population) have fibromyalgia.
PTSD is the most common cause of fibromyalgia.
It is estimated that approximately 6% of the population will develop post-traumatic stress disorder (PTSD) at some point in their lives. Approximately 12 million adults in the United States suffer from PTSD each year. Reportedly, about 8% of women and 4% of men will develop PTSD at some point in their lives. Other factors expected to boost market growth are:
Growth in Research and Development of New Treatments and Drugs for Fibromyalgia Rapid increase in elderly population
People’s perception that modern treatments are available to manage fibromyalgia FDA-approved drugs and government-sponsored clinical trials
Q: How are fibromyalgia drugs classified?
Fibromyalgia drugs can be divided into three segments:
Treatment type (symptomatic and targeted)
Drug class (antidepressants, anticonvulsants, muscle relaxants, analgesics) [Image 2d59861-3135-40500a6725241ad0b244-1.png&s3=59861-3135-91c5cafcb92591c8cb747d4b0fcb5aa4-532x325.png
Distribution channels (hospital pharmacies, drug stores, retail pharmacies, online pharmacies)
Question: Who are the prominent players in this fibromyalgia drug market? Frontrunners in the fibromyalgia drug market are Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., and Innovative Med Concepts, Inc. , Intec Pharma Ltd., and Astellas Pharma Inc. Each advances research and invests profitably in new treatments and pharmaceutical innovations.
Q: What is the current size of the fibromyalgia drug market and what are the challenges in its growth?
The global fibromyalgia treatment market is valued at USD 3 billion in 2022 and is projected to reach 4 billion by 2030, growing at a CAGR of 4% over the next decade .
However, drug side effects and treatment costs are some of the challenges that may hamper the market growth.
About us:-
Research Nester’s purpose is to provide clients with reliable research insights including growth indicators, challenges, trends and competitive landscape. We have the expertise to work with different market sectors to serve our clients the best possible and help them make smart decisions.

Details about this release:


Leave a Reply

Your email address will not be published.

%d bloggers like this: